Objective Patients with Alzheimer dementia often display poor sleep. Given that the disease is often associated with low endogenous levels of melatonin, exogenous melatonin administration may lead to improvements in sleep. Methods Randomized, placebo controlled study was carried out in 41 patients with probable Alzheimer disease. Melatonin (8. 5 mg immediate release and 1. 5 mg sustained release) (n =24) or placebo (n = 17) administered at 22:00 P. M. for 10 consecutive nights. The protocol sleep was measured continuously using actigraphy. Results There were no significant effects of melatonin,compared with placebo,on sleep and circadian rhythms. Conclusion This study failed to find a beneficial effect of exogenous melatonin.

Objective:To verify the efficacy and safety of daily oral minodronate in postmenopausal women with established osteoporosis.Methods:In this randomized, double-blinded, placebo-controlled trial, 262 postmenopausal women were enrolled. Patients were randomized to receive daily oral minodronate 1 mg with supplements of 500 mg calcium and 200 U vitamin D 3 ( n=130) or placebo ( n=132) with daily supplements of 500 mg calcium and 200 U vitamin D 3, for 48 weeks. The primary endpoint was the average bone mineral density (BMD) change in the lumbar vertebrae 48 weeks post-treatment. Secondary outcome measures was the incidence of vertebral fractures. Safety assessments included the rate of adverse events. Results:At the end of 48 weeks treatment, the average BMD change rate from baseline were: full analysis set results: (3.52±4.82)% in the minodronate group and (2.00±5.74)% in the placebo group; per-protocol set results: (3.99±5.05)% in the minodronate group and (2.07±6.20)% in the placebo group; the differences were all significant (all P<0.05). Vertebral fracture occured in 3 patients (2.3%, 3/132) in the placebo group, and 1 case (0.8%, 1/130) in the minodronate group ( P>0.05). The incidence of adverse events was 71.5% (93/130) in the minodronate group and 78.0% (103/132) in the placebo group ( P>0.05). Conclusion:Minodronate is effective and safe in the treatment of postmenopausal osteoporosis without severe side effects.

Cardiovascular disease has become a serious disease that threatens the health of human beings, cardiac output is an important indicator of cardiovascular function, monitoring cardiac output and related hemodynamic parameters have significant clinical value. This article summarizes the development history, principle, method, advantages and disadvantages of various monitoring technologies from three aspects:invasive, minimally invasive and noninvasive, the development and application of cardiac output monitoring technology are prospected.
Cardiac Output ; Hemodynamics ; Humans ; Monitoring, Physiologic ; instrumentation

Defibrillator is an important first aid equipment with people attach importance to life and health in today, people pay more attention to the development of defibrillator. This paper reviews the development history of the defibrillator, gives a brief introduction to the structure and working principle of the defibrillator, and then analyzes the key technology of defibrillator, compares the mainstream products on the market and prospects the development trend of defibrillator.
Defibrillators ; Electric Countershock ; First Aid ; Humans ; Technology ; Ventricular Fibrillation ; therapy